References
- Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat. Rev. Cardiol. 12(4), 199–211 (2015).
- Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in eskimos. Lancet 2(8140), 433–435 (1979).
- Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr. Opin. Lipidol. 17(4), 387–393 (2006).
- Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 13(6), 474–483 (2011).
- Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr. Med. Res. Opin. 32(2), 301–311 (2016).
- Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503), 92–101 (2014).
- Bäck M, Powell WS, Dahlen SE et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR review 7. Br. J. Pharmacol. 171(15), 3551–3574 (2014).
- Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs. Ther. 23(1), 41–48 (2009).
- Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized pro-resolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30(8), 2792–2801 (2016).
- Skarke C, Alamuddin N, Lawson JA et al. Bioactive products formed in humans from fish oils. J. Lipid Res. 56(9), 1808–1820 (2015).
- Murphy RC. Specialized pro-resolving mediators: do they circulate in plasma? J. Lipid Res. 56(9), 1641–1642 (2015).
- Thul S, Labat C, Temmar M, Benetos A, Bäck M. Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation. Eur. J. Prev. Cardiol. 24(9), 903–906 (2017).
- Van Noolen L, Bäck M, Arnaud C et al. Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. Prostaglandins Leukot. Essent. Fatty Acids 91(4), 111–117 (2014).
- Laguna-Fernandez A, Petri M, Thul S, Bäck M. Lipoxygenases and cardiovascular diseases. In: Lipoxygenases in Inflammation. Steinhilber D ( Ed.). Springer, Basel, Switzerland, 101–130 (2016).
- Petri MH, Laguna-Fernandez A, Arnardottir H et al. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br. J. Pharmacol. doi:10.1111/bph.13707 (2017) ( Epub ahead of print).
- Salic K, Morrison MC, Verschuren L et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250, 158–165 (2016).
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell’Infarto miocardico. Lancet 354(9177), 447–455 (1999).
- Oikawa S, Yokoyama M, Origasa H et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis 206(2), 535–539 (2009).
- Bosch J, Gerstein HC, Dagenais GR et al. Origin trial investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367(4), 309–318 (2012).
- Risk, Prevention Study Collaborative G. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368(19), 1800–1808 (2013).
- Piepoli MF, Hoes AW, Agewall S et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37(29), 2315–2381 (2016).
- Siscovick DS, Barringer TA, Fretts AM et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 135(15), e867–e884 (2017).